STAAR Surgical Q4 net sales $64M, ICL units +20% YoY; FY2023 ICL sales guidance ~$340M

STAAR SURGICAL CO

2023-Q3 EPS reported $0.80 revenue$284,391,000

Q4 net sales $64.0M (+9% YoY); constant currency net sales $67.9M (+15%).
ICL sales $61.2M (+15% YoY); ICL units +20% YoY; U.S. ICL units +109%.
FY2022 net sales $284.4M (+23%); ICL sales $269.7M (+27%); ICL units +33%.
FY2022 GAAP EPS $0.78 vs $0.50 prior year; adjusted EPS $1.22 vs $0.87.
FY2023 ICL sales guidance ~$340M, representing 26% YoY growth.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

STAAR SURGICAL CO reported fourth quarter and fiscal year ended December 30, 2022 results: revenue $64.0 million, net income $0.12 per diluted share, EPS $0.12 per diluted share. Guidance reaffirmed.

Period: fourth quarter and fiscal year ended December 30, 2022
Revenue: $64.0 million
Net income: $0.12 per diluted share
EPS: $0.12 per diluted share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

of implantable lenses for the eye, today reported financial results for the fourth quarter and fiscal year ended December 30, 2022. Fourth Quarter 2022 Overview • Net Sales of $64.0 Million Up 9% and Constant Currency Net Sales of $67.9 Million Up 15% from Prior Year Quarter • ICL Sales of $61.2 Million Up 15% and Constant Currency ICL Sales of $64.3 Million Up 21%

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

STAAR SURGICAL CO filing history →

Source: SEC EDGAR

accession 0001564590-23-002118

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.